Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic Study of Minocycline in MAC-PD
NCT05861258Phase 2Terminated
- Sponsor
- Radboud University Medical Center
- Start
- May 2023
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of minocycline in mycobacterium avium complex pulmonary disease (MAC-PD), sponsored by Radboud University Medical Center. Primary endpoint: Pharmacokinetic parameters of minocycline in MAC-PD patients without concurrent use of rifampicin at Day 5. Started May 2023; status: terminated.
02
Drugs
minocycline
03
Conditions
mycobacterium avium complex pulmonary disease (MAC-PD)
Beyond the preview
Go deeper on NCT05861258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05861258.